Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donepezil + tandospirone is a combination therapy consisting of two small molecule drugs, donepezil and tandospirone. Donepezil is an acetylcholinesterase inhibitor primarily used to treat cognitive symptoms in Alzheimer's disease by increasing acetylcholine levels in the brain, thereby improving memory and cognition. Tandospirone is an anxiolytic and antidepressant of the azapirone class that acts as a selective partial agonist at the serotonin 5-HT1A receptor, with additional weak activity at other receptors. The combination has been studied for its potential to improve both cognitive function and neuropsychiatric symptoms (such as anxiety) in patients with Alzheimer's disease who present with comorbid anxiety or behavioral disturbances[6][1]. Clinical studies suggest that while both agents may improve cognition, the addition of tandospirone provides significant benefit for anxiety symptoms and behavioral disturbances compared to donepezil alone[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on donepezil + tandospirone.